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Administration of gammaglobulins to individuals without specific anti-Borrelia burgdorferi antibodies may
lead to immunoglobulin G (IgG) conversion as detected by enzyme-linked immunosorbent assay (ELISA).
In some cases however, complementary techniques such as Western blot or avidity will be of prime
importance in distinguishing the start of an infection from the passive immunization induced by the
gammaglobulins. In all cases, the key element before reaching conclusions in relation to any of these
investigations remains the confrontation between the clinical context and the biological findings. This is the
scenario that has been followed in our observation.
Clin Microbiol Infect 2001; 7: 697–699
CLINICAL CONTEX T
A 5-year-old child was admitted to the hospital presumptive
with a diagnosis of meningitis. Over the previous 10 days, he
had been suffering from pain in the legs, and during the last 48 h
he had been vomiting, had experienced slight photophobia, had
shown difficulty in walking, and had been in pain but not
febrile. The parents reported no diarrhea and no gastroenteritis.
Clinical examination revealed painful mobility of the neck.
Seventy-two hours after admission, the child lost the osteo-
tendinous reflex and developed speech difficulty. Lyme neuro-
borreliosis was suspected even though there was neither history
of a tick bite nor erythema migrans over the previous
months.
The overall investigations for blood tests did not present
anything particular. Prior to lumbar puncture, the brain and full
spine magnetic resonance imaging with gadolinium was nor-
mal. The cerebrospinal fluid (CSF) results were as follows:
leukocytes, 5/mm3; erythrocytes, 1/mm3; bacterial culture,
sterile. Testing for anti-Borrelia burgdorferi IgG and IgM anti-
bodies in the CSF was negative with both ELISA and Western
blot. However, ELISA for IgM antibody was positive in the first
serum sample (Table 1). A search for B. burgdorferi DNA in the
CSF using the polymerase chain reaction (PCR) was negative.
The CSF had an increased total protein of 227 mg/dL (normal
value 0–45 mg/dL) and an increase in quantitative IgG and IgM
proteins at 27 mg/dL (normal value 0–4 mg/dL), and 4.80 mg/
dL (normal value 0–0.80 mg/dL), respectively. The glucose was
slightly increased to 70 mg/dL (normal value 45–65 mg/dL)
and the lactic acid was normal at 2.1 mmol/L (normal value
1.1–2.4 mmol/L).
To identify the potential cross-reactions, which may
cause false-positive IgM with ELISA, we undertook in-depth
study for syphilis and brucellosis and for infection with
Epstein–Barr virus and Chlamydia. All these investigations were
negative.
Agarose electrophoresis of CSF performed simultaneously
with the serum sample did not reveal any oligoclonal IgG
pattern suggestive of intrathecal synthesis of IgG antibody.
Electromyography (EMG) showed that the nerve conduction
velocities in the legs were clearly slowed down (32–37 m/s;
normal value >45 m/s) while the latencies of both external
popliteal sciatic nerves were strongly increased (8.9 and 10.5 ms;
normal value <5 ms). This indicated an acute inflammatory
demyelinating polyneuropathy.
In addition to these EMG abnormalities and the motor
weakness, the increased total CSF protein, and an albu-
minocytological dissociation with few cells, were characteri-
stic of Guillain–Barre´ syndrome. Until this diagnosis was
established, no antibiotic treatment had been given for a
presumptive neuroborreliosis. The patient was then treated
for 5 days, from the 5th day following admission, with in-
travenous gammaglobulins (Sandoglobuline) at a dose of
400 mg/kg. This treatment was successful and the child
improved within a few days. He recovered his mobility com-
pletely but remained under observation for several months. So
far, after 2 years of follow-up, no relapse of the disease has been
observed.
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DISCUSSION
In our case, the diagnosis of neuroborreliosis was questionable
since tests for the intrathecal synthesis of Borrelia burgdorferi-
specific IgG and IgM antibody, and for borrelial DNA in the
CSF by PCR were negative. In addition, the tests for specific
IgG and IgM antibodies using Western blot were negative in the
first serum sample. This created the need for sequential serum
samples which could demonstrate a seroconversion after a lag
phase. We now know that some new and promising immu-
noassays improve the reliability of antibody detection in the
early phase [4–7]. None of these, however, were available to our
laboratory.
Whilst the ELISA detected the IgM antibody in all three
serum samples, yielding a strong suggestion of early dissemi-
nated borrelia infection [8], the Western blot on a second step,
did not confirm the specificity of the antibody.
This strategy, based on Western blot as a second-tier test,
is one recommended by the Centers for Disease Control
(Rockville, USA) to resolve any positive or equivocal result
found with a sensitive first-line ELISA assay [1]. In our endemic
area, serological determinations of IgM-specific antibody with
ELISA may be hampered by cross-reactions, which tend to
decrease the positive predictive value of the test [9]. Cross-
reactions are less frequent with Western blot because each
antigen isolated from the spectrum of B. burgdorferi reacts
individually, as opposed to the antigen mixture used in the
ELISA [10]. Such cross-reactions emerge in clinical conditions
when epitopes of B. burgdorferi show homology with virus or
bacterial epitopes in the host. There may eventually be a
stimulation of B lymphocytes by Epstein–Barr virus infection,
leading to a polyclonal hyperactivity of B cells. Cross-reactions
have also been reported from individuals living in tropical
countries at a rate of 98% for ELISA and 57% for Western
blot [11].
In our patient, the evidence for an IgG seroconversion
was supported by the presence of IgG antibody in the second
sample (day 9), as compared with the negative results of the
first day after admission. Although on the one hand Western
blot confirmed this seroconversion based on the IgG anti-
body, on the other hand only antigens indicative of old immu-
nization, i.e. P100, P39 and P18, were detected. Indeed,
any antigen like OspC, P41 or their combination with P18.5
and P18, which are specific of early localized or early dis-
seminated disease, were missing [12]. In addition, our in-house
technique of avidity demonstrated a maturation rate of IgG at
75 and 79%, on samplings of day 9 and 30, respectively.
To assess the extent to which the intravenous gammaglo-
bulins were involved in the seroconversion, we investigated
the corresponding concentration of anti-B. burgdorferi with
ELISA and Western blot. The primary solution of gamma-
globulins was diluted into a negative serum sample to 10 mg/
mL; from this, the working solutions were 1 : 231 for IgG
antibody and 1 : 42 for IgM antibody. As expected, IgG anti-
B. burgdorferi was positive both with ELISA and Western
blot and showed a characteristic high avidity value. Overall,
data from intravenous gammaglobulins as well as from the
sequential serum samples were the proof of past immunity
relative to B. burgdoferi.
To evaluate the potential role of Campylobacter jejuni in the
occurrence of the Guillain–Barre´ syndrome [13,14] – up to 36%
of patients present significantly high titers of specific antibody –
a complement fixation technique was requested from the
National Reference Laboratory of the University Hospital,
St. Pierre in Brussels (Professor J. P. Butzler, Dr. D. Van Beers
and M. Duys). The antibody titers were low at 1/32, 1/32 and
Table1 Serology of the serum samples and commercial gammaglobulins
Units in serum samples
Tests
Cut off
Units Admission Day9 Day30
Gamma-
globulins
IgGEIAa <6UI/mL 0 18 7 11
IgMEIAa <0.34 0.66 (Pos) 0.62 (Pos) 0.68 (Pos) Neg
IgGWestern blotb <Score 6 0 12
P100
P41
P39
P18
10
P100
P39
P18
30
P100
P41
P39
OspA
P18
IgMWestern blotb <Score 6 0 0 0 NT
IgGavidityc NA 75% 79% 45%
aEnzygnost Borreliosis, Dade Behring; bRecomblot Borrelia IgG/IgM, Mikrogen [1,2]; cHouse technique with Dade Behring avidity reagent on BEPIII [3].
NA, non-applicable; NT, not tested.
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1/64 on days 1, 9 and 30, respectively. They were indicative of
past immunity since no significant change was detected. The
detection of HLA-B35, which is a potential marker for pre-
disposition to a Guillain–Barre´ syndrome [15], was negative
(Professor M. De Bruye`re, Immunohematology Department,
Faculty of Medicine, Catholic University of Louvain, UCL,
Brussels). Stool culture with a view to detecting Campylobacter
bacteria was not performed.
B. burgdorferi has been suspected to be associated with Guil-
lain–Barre´ syndrome [16,17]. However, in our case diagnosis of
Lyme borreliosis was definitely ruled out because the serocon-
version of the specific IgG antibody was demonstrated as being
due to passive immunization by the gammaglobulins. Such a
serological pitfall has been more frequently observed in toxo-
plasmosis, from which one case reported in the literature
involved a pregnant woman [18].
We should remember that Lyme borreliosis is a clinical
diagnosis with a serological test for antibody to be used as just
one piece of information in a complex picture. Also, this
observation is an opportunity to emphasize the crucial integra-
tion of the clinical background with the serological profile in
order to optimize the interpretation of all investigations.
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